Issue Date: February 16, 2009
Senate Bill Targets Generic Drug Delays
Legislation introduced in the Senate would prohibit pharmaceutical companies with brand-name medicines from paying makers of generic drugs to delay introduction of the less expensive but equivalent products. “It’s time to stop these drug company pay-for-delay deals that only serve the profits of the companies involved and deny consumers access to affordable generic drugs,” says Sen. Herbert H. Kohl (D-Wis.), the bill’s chief sponsor. “With this legislation (S. 369), we . . .
To view the rest of this content, please log in with your ACS ID.
- Chemical & Engineering News
- ISSN 0009-2347
- Copyright © American Chemical Society